ReviewBMC medical research methodology2022
Assessing transferability in systematic reviews of health economic evaluations - a review of methodological guidance.
Review in BMC medical research methodology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review.PharmacoEconomics · 2023Pooled it
- The cost-effectiveness of different types of educational interventions in type II diabetes mellitus: A systematic review.Frontiers in pharmacology · 2022Pooled it
- Global Mapping of National Health Economic Evaluation Guidelines: Evidence from 40 Countries.Pharmaceutical medicine · 2026Review
- Meta-Analysis of Incremental Net Benefit from Trial-Based Health Economic Evaluations in R: A Tutorial.PharmacoEconomics · 2026Review
- Landscape Analysis of Literature Using Quantitative Approaches to Synthesize Economic Evaluation Studies: A Scoping Review.PharmacoEconomics · 2026Review
- Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Economic evaluation of school scoliosis screening in Gannan Tibetan autonomous prefecture, Gansu Province: a cost-utility analysis based on decision tree-Markov model.Frontiers in public health · 2026Article
- Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies.PharmacoEconomics · 2026Article
- An Algorithm for Incorporating Economic Evidence Into Clinical Practice Guidelines: Application to the Spanish Guideline for the Management of Chronic Primary Pain.Clinical and public health guidelines · 2025Article
- How Professional and Market Logics and the Conflict between Institutional Demands Affect Hospital Accreditation Compliance: A Multiple-Case Study in Brazil.Healthcare (Basel, Switzerland) · 2024Article
- Research Priorities to Increase Confidence in and Acceptance of Health Preference Research: What Questions Should be Prioritized Now?The patient · 2024Article
- Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations.Blood advances · 2023Article
- Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward.PharmacoEconomics · 2023Article
- A Scoping Review of Economic Evaluations to Inform the Reorientation of Preventive Health Services in Australia.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFor assessing cost-effectiveness, Health Technology Assessment (HTA) organisations may use primary economic evaluations (P-HEs) or Systematic Reviews of Health Economic evaluations (SR-HEs). A prerequisite for meaningful results of SR-HEs is that the results from existing P-HEs are transferable to the decision context (e.g, HTA jurisdiction). A particularly pertinent issue is the high variability of costs and resource needs across jurisdictions. Our objective was to review the methods documents of HTA organisations and compare their recommendations on considering transferability in SR-HE.
methodsWe systematically hand searched the webpages of 158 HTA organisations for relevant methods documents from 8th January to 31st March 2019. Two independent reviewers performed searches and selected documents according to pre-defined criteria. One reviewer extracted data in standardised and piloted tables and a second reviewer checked them for accuracy. We synthesised data using tabulations and in a narrative way.
resultsWe identified 155 potentially relevant documents from 63 HTA organisations. Of these, 7 were included in the synthesis. The included organisations have different aims when preparing a SR-HE (e.g. to determine the need for conducting their own P-HE). The recommendations vary regarding the underlying terminology (e.g. transferability/generalisability), the assessment approaches (e.g. structure), the assessment criteria and the integration in the review process.
conclusionOnly few HTA organisations address the assessment of transferability in their methodological recommendations for SR-HEs. Transferability considerations are related to different purposes. The assessment concepts and criteria are heterogeneous. Developing standards to consider transferability in SR-HEs is desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.